Goldman Sachs Upgrades BioNTech to Buy, Sees Strong Cancer Therapy Potential
Goldman Sachs raises BioNTech to Buy, citing its strong position in oncology and upcoming 2026 data that could boost new cancer therapies.
/ 7 items
#BNTX↓
FDA Memo on Vaccine Deaths Sends Moderna, Novavax Stocks Tumbling
Moderna and Novavax shares drop 5-6% after FDA's vaccine chief links COVID-19 shots to 10 children's deaths and announces stricter vaccine approval standards.
Bristol Myers Squibb Defies Patent Cliff: Blockbuster Sales of Opdivo and Eliquis Drive Raised Forecast
BMS crushed Q3 goals and boosted its yearly forecast. New blockbusters like Opdivo and Eliquis cover losses from older generic drugs.
Moderna Rises on Release of Positive Results for the Reformulated COVID Vaccine
New COVID vaccines from Moderna & Pfizer show strong protection against the dominant LP.8.1 variant. Moderna's Spikevax (for high-risk 6mo-64yrs & all 65+) boosted antibodies 8x. Pfizer's also effective. No new safety issues found.
Major Report Sparks Debate: Are COVID Vaccines Linked to Child Deaths?
Trump officials plan to link COVID vaccines to 25 child deaths using unverified VAERS data. This news dropped vaccine makers' shares. HHS calls it "pure speculation", while Moderna states its vaccine is rigorously monitored with no new safety concerns.
New COVID-19 Vaccine Rollout Faces Headwinds Amid Regulatory Shifts and Fresh Data
Health Secretary Robert F. Kennedy Jr.'s regulatory changes cause a rocky COVID vaccine rollout with narrowed FDA approval (65+, high risk). Pfizer's new data shows good LP.8.1 protection. A key CDC meeting on Sept. 18 will address access & coverage, amidst plummeting sales.